{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"data_sharing_plan":["IPD Sharing (as of February 2022): No"],"condition":["Colorectal Cancer","Colorectal Neoplasms","Circulating Tumor DNA","Adjuvant Chemotherapy","Progression Free Survival"],"disease":["Colorectal Cancer","Colorectal Neoplasms","Circulating Tumor Dna","Adjuvant Chemotherapy","Progression Free Survival"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2290096"],"location":["Denmark"],"study_start_month":["10"],"keyword":["Oxaliplatin"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer","description":"A open label 1:1 randomized phase II exploratory study investigating adjuvant therapy in patients with molecular biologically detectable residual disease after primary resection for localized colorectal tumors.","dates":{"creation":"2018-10-15"},"accession":"2290096","cross_references":{"ClinicalTrials___gov":["NCT03748680"]}}